Limin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Limin Xu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Beibei Li
The Second Military Medical University
1 shared publication Bin Peng
Sino-French Cooperative Central Lab, Shanghai Gongli Hospital, the Second Military Medical University, Pudong New District, Shanghai, People's Republic of China
1 shared publication- Denghai Zhang
Shanghai Health Commission Key Lab of Artificial Intelligence (AI)-Based Management of Inflammation and Chronic Diseases, Sino-French Cooperative Central Lab, Shanghai Pudong Gongli Hospital, China
1 shared publication - Dongjun Dai
Department of Radiation Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
1 shared publication Fanfan Cao
Sino-French Cooperative Central Lab, Shanghai Gongli Hospital, the Second Military Medical University, Pudong New District, Shanghai, People's Republic of China
1 shared publicationHaiwang Guan
Ningbo Medical Center, Lihuili Hospital, Department of Cardiology, Ningbo University
1 shared publication
Latest Publications
- Open Access
- 4 November 2022
- Published by Springer Nature in Research Square
New diagnosis for hepatocellular carcinoma via hsa_circ_0097009
Background Although circular RNAs take a key part in the regulation of cancer, its role in the diagnosis and prognosis of hepatocellular carcinoma (HCC) still unclear. This study investigated the diagnostic and prognostic usefulness of hsa_circ_0097009 in HCC. Methods qRT-PCR assay was performed to detect the presence of hsa_circ_0097009 in plasma collected from 30 HCC patients and 30 healthy controls. Receiver operating characteristic (ROC) curve, Cox regression, and Kaplan–Meier curve analyses were applied to evaluate the clinical diagnostic and prognostic values of hsa_circ_0097009. Results The experimental data suggested that hsa_circ_0097009 expression of HCC plasma and cell lines is upregulated. The plasma hsa_circ_0097009 level of HCC patients was linked to tumor diameter (P = 0.026) and alpha-fetoprotein (AFP) expression level (P = 0.019). In addition, the plasma level of hsa_circ_0097009 decreased markedly after surgery to remove the tumor. Moreover, the level of plasma of hsa_circ_0097009 in HCC patients was increased compared with healthy controls (P < 0.0001) and hepatitis B patients. ROC curve reflected that the area under the curve (AUC) of plasma hsa_circ_0097009 to distinguish HCC from healthy controls and hepatitis B patients were 0.9368 (95 percent CI = 0.8874–0.9862) and 0.9067 (95 percent CI = 0.8439–0.9695), respectively, with the same sensitivity 0.9779 and the same specificity 0.6889. Furthermore, the AUC value of hsa_circ_0097009 combined with AFP for distinguishing HCC from healthy controls was 0.9822 (95 percent CI = 0.9682–0.9961), with the sensitivity 0.9889 and specificity 0.667. The plasma hsa_circ_0097009 low expression group had a considerably longer overall survival (OS) than the high expression group. Conclusion The study suggests that hsa_circ_0097009 could be used as a new potential biomarker in diagnoses and prognoses of HCC patients.
- 4 November 2022
- Published by Springer Nature in Research Square
Open AccessNew diagnosis for hepatocellular carcinoma via hsa_circ_0097009
Background Although circular RNAs take a key part in the regulation of cancer, its role in the diagnosis and prognosis of hepatocellular carcinoma (HCC) still unclear. This study investigated the diagnostic and prognostic usefulness of hsa_circ_0097009 in HCC. Methods qRT-PCR assay was performed to detect the presence of hsa_circ_0097009 in plasma collected from 30 HCC patients and 30 healthy controls. Receiver operating characteristic (ROC) curve, Cox regression, and Kaplan–Meier curve analyses were applied to evaluate the clinical diagnostic and prognostic values of hsa_circ_0097009. Results The experimental data suggested that hsa_circ_0097009 expression of HCC plasma and cell lines is upregulated. The plasma hsa_circ_0097009 level of HCC patients was linked to tumor diameter (P = 0.026) and alpha-fetoprotein (AFP) expression level (P = 0.019). In addition, the plasma level of hsa_circ_0097009 decreased markedly after surgery to remove the tumor. Moreover, the level of plasma of hsa_circ_0097009 in HCC patients was increased compared with healthy controls (P < 0.0001) and hepatitis B patients. ROC curve reflected that the area under the curve (AUC) of plasma hsa_circ_0097009 to distinguish HCC from healthy controls and hepatitis B patients were 0.9368 (95 percent CI = 0.8874–0.9862) and 0.9067 (95 percent CI = 0.8439–0.9695), respectively, with the same sensitivity 0.9779 and the same specificity 0.6889. Furthermore, the AUC value of hsa_circ_0097009 combined with AFP for distinguishing HCC from healthy controls was 0.9822 (95 percent CI = 0.9682–0.9961), with the sensitivity 0.9889 and specificity 0.667. The plasma hsa_circ_0097009 low expression group had a considerably longer overall survival (OS) than the high expression group. Conclusion The study suggests that hsa_circ_0097009 could be used as a new potential biomarker in diagnoses and prognoses of HCC patients.
- 11 December 2017
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 65 (3) , 390-396
Effects of celastrol on Tau hyperphosphorylation and expression of HSF‐1 and HSP70 in SH‐SY5Y neuroblastoma cells induced by amyloid‐β peptides
To observe the effects of celastrol on Tau hyperphosphorylation induced by amyloid‐β peptides (Aβ) in SH‐SY5Y neuroblastoma cells, the changes of Tau hyperphosphorylation and the expression of heat shock protein 90 (HSP90), HSP70, and heat shock factor 1 (HSF‐1) in SH‐SY5Y cells treated with Aβ1–42 and celastrol were measured. Tau hyperphosphorylation and HSP90 expression induced by Aβ1–42 was also measured by Western blotting after HSP70 or HSF‐1 knockdown by siRNA. The interaction between HSP70 and Tau or HSP70 and carboxyl terminus of HSP70 interacting protein (CHIP) was measured by co‐immunoprecipitation. Compared with the control group, the expressions of HSP70 and HSF‐1 were markedly decreased after the induction of Aβ1–42, whereas the expressions of HSP90, Tau phospho S199/202, and Tau phospho S396 were markedly increased. Meanwhile, both celastrol treatment and knockdown of HSP70 or HSF‐1 in SH‐SY5Y cells significantly inhibited the Tau hyperphosphorylation and HSP90 expression induced by Aβ1–42. Moreover, celastrol treatment had no effects on Aβ1–42‐induced decreased expression of HSP70 and HSF‐1, Tau ubiquitination, and the interaction of HSP70/Tau and HSP70/CHIP. These results suggest that celastrol‐inhibited Tau hyperphosphorylation may not be dependent on the cause of HSF‐1/HSP70/CHIP‐mediated ubiquitination of Tau.
- 11 December 2017
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 65 (3) , 390-396
Effects of celastrol on Tau hyperphosphorylation and expression of HSF‐1 and HSP70 in SH‐SY5Y neuroblastoma cells induced by amyloid‐β peptides
To observe the effects of celastrol on Tau hyperphosphorylation induced by amyloid‐β peptides (Aβ) in SH‐SY5Y neuroblastoma cells, the changes of Tau hyperphosphorylation and the expression of heat shock protein 90 (HSP90), HSP70, and heat shock factor 1 (HSF‐1) in SH‐SY5Y cells treated with Aβ1–42 and celastrol were measured. Tau hyperphosphorylation and HSP90 expression induced by Aβ1–42 was also measured by Western blotting after HSP70 or HSF‐1 knockdown by siRNA. The interaction between HSP70 and Tau or HSP70 and carboxyl terminus of HSP70 interacting protein (CHIP) was measured by co‐immunoprecipitation. Compared with the control group, the expressions of HSP70 and HSF‐1 were markedly decreased after the induction of Aβ1–42, whereas the expressions of HSP90, Tau phospho S199/202, and Tau phospho S396 were markedly increased. Meanwhile, both celastrol treatment and knockdown of HSP70 or HSF‐1 in SH‐SY5Y cells significantly inhibited the Tau hyperphosphorylation and HSP90 expression induced by Aβ1–42. Moreover, celastrol treatment had no effects on Aβ1–42‐induced decreased expression of HSP70 and HSF‐1, Tau ubiquitination, and the interaction of HSP70/Tau and HSP70/CHIP. These results suggest that celastrol‐inhibited Tau hyperphosphorylation may not be dependent on the cause of HSF‐1/HSP70/CHIP‐mediated ubiquitination of Tau.
- Open Access
- 1 January 2014
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 21 (11) , 1109-1120
A Replication Study and a Meta-Analysis of the Association between the CDKN2A rs1333049 Polymorphism and Coronary Heart Disease
Aim: The aim of this study was to assess whether rs1333049 was associated with coronary heart disease (CHD) in Han Chinese. Methods: This case-control study was involved with 599 CHD patients and 591 non-CHD controls. Meanwhile, a comprehensive meta-analysis was also conducted to establish the contribution of rs1333049 to CHD. Results: Our results showed that rs1333049 increased the risk of CHD by 38% (OR=1.38, 95% CI=1.18-1.62). A breakdown analysis by gender further indicated that rs1333049 increased the risk of CHD in men by 29% (OR=1.29, 95% CI=1.05-1.58) and in women by 64% (OR=1.64, 95% CI=1.25-2.16). A follow-up subgroup analysis by age showed there was a significant association between rs1333049 and CHD in women younger than 65 (≤55 years: p=0.001, 55-65 years: p=0.008) and in men aged between 55 and 65 years (p=0.005). Our meta-analysis was involved with 21 studies (25 stages) among 20969 cases and 34114 controls. Our results showed that rs1333049 led to a significantly increased risk of CHD (OR=1.30, 95% CI=1.21-1.39). Further subgroup analyses by ethnicity showed rs1333049 increased the CHD risk by 30% in Europeans (OR=1.30, 95% CI=1.16-1.47) and 27% in Asians (OR=1.27, 95% CI=1.22-1.33). Conclusions: Our case-control study and meta-analysis suggest that rs1333049 is a useful risk marker of CHD.
- 1 January 2014
- Published by Japan Atherosclerosis Society in Journal of Atherosclerosis and Thrombosis
- Vol. 21 (11) , 1109-1120
Open AccessA Replication Study and a Meta-Analysis of the Association between the CDKN2A rs1333049 Polymorphism and Coronary Heart Disease
Aim: The aim of this study was to assess whether rs1333049 was associated with coronary heart disease (CHD) in Han Chinese. Methods: This case-control study was involved with 599 CHD patients and 591 non-CHD controls. Meanwhile, a comprehensive meta-analysis was also conducted to establish the contribution of rs1333049 to CHD. Results: Our results showed that rs1333049 increased the risk of CHD by 38% (OR=1.38, 95% CI=1.18-1.62). A breakdown analysis by gender further indicated that rs1333049 increased the risk of CHD in men by 29% (OR=1.29, 95% CI=1.05-1.58) and in women by 64% (OR=1.64, 95% CI=1.25-2.16). A follow-up subgroup analysis by age showed there was a significant association between rs1333049 and CHD in women younger than 65 (≤55 years: p=0.001, 55-65 years: p=0.008) and in men aged between 55 and 65 years (p=0.005). Our meta-analysis was involved with 21 studies (25 stages) among 20969 cases and 34114 controls. Our results showed that rs1333049 led to a significantly increased risk of CHD (OR=1.30, 95% CI=1.21-1.39). Further subgroup analyses by ethnicity showed rs1333049 increased the CHD risk by 30% in Europeans (OR=1.30, 95% CI=1.16-1.47) and 27% in Asians (OR=1.27, 95% CI=1.22-1.33). Conclusions: Our case-control study and meta-analysis suggest that rs1333049 is a useful risk marker of CHD.